Evidence map›Paper›PMID 34841720›Full record

ArticleClinical and translational medicine2021

The multicellular signalling network of ovarian cancer metastases.

Leah Sommerfeld, Florian Finkernagel, Julia M Jansen, Uwe Wagner, Andrea Nist, Thorsten Stiewe, Sabine Müller-Brüsselbach, Anna M Sokol, Johannes Graumann, Silke Reinartz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Processed Products ofAnti-cancer agents in medicinal chemistry · 2025
    Article
  7. Unleashing Wnts: Wnt Ligands Fuel Cancer Spread.Journal of cancer biology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Leah SommerfeldDepartment of Translational Oncology, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Florian FinkernagelDepartment of Translational Oncology, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Julia M JansenClinic for Gynecology, Gynecological Oncology and Gynecological Endocrinology, University Hospital (UKGM), Marburg, Germany.
Uwe WagnerClinic for Gynecology, Gynecological Oncology and Gynecological Endocrinology, University Hospital (UKGM), Marburg, Germany.
Andrea NistGenomics Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Thorsten StieweGenomics Core Facility, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Sabine Müller-BrüsselbachDepartment of Translational Oncology, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Anna M SokolThe German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Johannes GraumannThe German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0000-0002-3015-5850
Silke ReinartzDepartment of Translational Oncology, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.
Rolf MüllerDepartment of Translational Oncology, Center for Tumor Biology and Immunology (ZTI), Philipps University, Marburg, Germany.ORCID 0000-0003-3339-4248
Philipps University of Marburg · DEGynecologic Oncology Group · USMax Planck Institute for Heart and Lung Research · DE

Funding

Deutsche Krebshilfe (German Cancer Aid) 70113255
6 · The paper itself

Abstract

backgroundTranscoelomic spread is the major route of metastasis of ovarian high-grade serous carcinoma (HGSC) with the omentum as the major metastatic site. Its unique tumour microenvironment with its large populations of adipocytes, mesothelial cells and immune cells establishes an intercellular signaling network that is instrumental for metastatic growth yet poorly understood.

methodsBased on transcriptomic analysis of tumour cells, tumour-associated immune and stroma cells we defined intercellular signaling pathways for 284 cytokines and growth factors and their cognate receptors after bioinformatic adjustment for contaminating cell types. The significance of individual components of this network was validated by analysing clinical correlations and potentially pro-metastatic functions, including tumour cell migration, pro-inflammatory signal transduction and TAM expansion.

resultsThe data show an unexpected prominent role of host cells, and in particular of omental adipocytes, mesothelial cells and fibroblasts (CAF), in sustaining this signaling network. These cells, rather than tumour cells, are the major source of most cytokines and growth factors in the omental microenvironment (n = 176 vs. n = 13). Many of these factors target tumour cells, are linked to metastasis and are associated with a short survival. Likewise, tumour stroma cells play a major role in extracellular-matrix-triggered signaling. We have verified the functional significance of our observations for three exemplary instances. We show that the omental microenvironment (i) stimulates tumour cell migration and adhesion via WNT4 which is highly expressed by CAF; (ii) induces pro-tumourigenic TAM proliferation in conjunction with high CSF1 expression by omental stroma cells and (iii) triggers pro-inflammatory signaling, at least in part via a HSP70-NF-κB pathway.

conclusionsThe intercellular signaling network of omental metastases is majorly dependent on factors secreted by immune and stroma cells to provide an environment that supports ovarian HGSC progression. Clinically relevant pathways within this network represent novel options for therapeutic intervention.

Indexed as

Cell MovementFemaleGene Regulatory NetworksHumansNeoplasm MetastasisOvarian NeoplasmsSignal Transductionadipocytecarcinoma-associated fibroblastHSP70mesothelial cellmetastasisomentumovarian carcinomasignaling networktumour microenvironmentWNT4

Identifiers

PMID34841720
PMCPMC8574964
OpenAlexW3212026441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.